Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid [tretinoin] in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Next Previous
Search
Trial Profile

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid [tretinoin] in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tretinoin (Primary) ; Cytarabine; Etoposide; Etoposide
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AMLSG 15-10

Most Recent Events

  • 31 Jul 2018 Status changed from active, no longer recruiting to completed.
  • 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
  • 14 Oct 2014 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top